Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Bloodless single/tandem ASCT can be done safely for selected JW MM patients with no significant difference in...

More than 28% of the analyzed dietary supplements pose a potential risk of unintentional doping. Athletes and their teams need to be aware of...

Deciding on the smallest change in an outcome that constitutes a clinically meaningful treatment effect (ie, the minimum clinically important difference [MCID]) is fundamental...

Blue Cross Blue Shield of Michigan...

Barbers and nurse practitioners are an ideal partnership when seeking to disrupt the CRC health care disparity. Members of the Black community who may...

Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial...

The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron...

  • 1575249242620276736 Profile photo of Madelyn

    BOOSTERS: Japanese study, median age 68, 3rd dose (1st booster) improves severe disease. In US, 71% of those >65 have had 1st booster (3rd dose) - need to increase booster (now Omicron specific) rate in older people in US https://t.co/I9HYk23uUJ - view on twitter

Adverse cardiac remodelling is the main determinant of patient prognosis in degenerative valvular heart disease (VHD). However, to give an indication for valvular intervention,...

This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory...

Among participants with LDL cholesterol ≥190 mg/dl, gene sequencing identified an FH mutation...